Biomea Fusion, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent
Biomea Fusion, Inc. (BMEA) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent of -1.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent · last filed 2026-03-24
- Biomea Fusion, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2024 was -1.00%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2023 was -1.00%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2022 was -1.10%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2021 was -1.50%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | -1.00% 10-K · filed 2026-03-24 |
| 2023-12-31 | -1.00% 10-K · filed 2026-03-24 |
| 2022-12-31 | -1.10% 10-K · filed 2025-03-31 |
| 2021-12-31 | -1.50% 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |